The SPDR S&P Biotech ETF (XBI) is an exchange-traded fund designed to provide exposure to the U.S. biotechnology sector. The ETF is managed by State Street Global Advisors (SPDR) and trades under the ticker XBI on the NYSE Arca.

Classified as a sector-focused equity ETF centered on biotechnology, the fund seeks to reflect, before fees and expenses, the performance of the S&P Biotechnology Select Industry Index.

The ETF follows a passive management strategy, maintaining a portfolio structured to replicate the composition and weighting of its benchmark index. Unlike many traditional market-cap-weighted ETFs, XBI’s benchmark uses an equal-weighted methodology, reducing concentration in mega-cap companies while increasing exposure to smaller biotechnology firms.

Diversification and sector exposure

XBI provides exposure primarily associated with:

• Biotechnology.
• Drug development.
• Genetic therapies.
• Immunotherapy.
• Pharmaceutical research.
• U.S. small-cap and mid-cap companies.
• Healthcare innovation.
• U.S. healthcare sector.

The ETF’s performance is particularly sensitive to healthcare-sector conditions, the U.S. regulatory environment, and clinical-trial outcomes involving biotechnology companies.

Changes in interest rates, availability of research-and-development financing, and FDA decisions may directly affect the fund’s behavior. The ETF may also reflect developments associated with artificial intelligence used in drug discovery, genetic innovation, and emerging medical therapies.

Structure and costs

XBI shares trade on the secondary market on the NYSE Arca during regular trading hours. Share creation and redemption occur through authorized participants, a mechanism intended to help align the ETF’s market price with its net asset value (NAV).

The fund charges a management fee as outlined in its prospectus and does not apply a performance fee. XBI may distribute income derived from dividends paid by companies held within the portfolio.

Because the ETF maintains concentrated exposure to biotechnology companies and meaningful participation in smaller-cap firms, its performance may exhibit elevated volatility and strong sensitivity to regulatory and clinical developments.

History and evolution of the ETF

The SPDR S&P Biotech ETF was launched in 2006 during a period marked by expansion in healthcare- and medical-innovation-focused sector ETFs within the U.S. market.

Since inception, the fund has reflected movements associated with the American biotechnology industry, including advances in genetic therapies, regulatory developments, and financing cycles for medical research companies.

In recent years, XBI has reflected volatility across biotechnology companies, advances in precision medicine, growth in artificial intelligence applications within healthcare, and changing financial conditions across pharmaceutical innovation markets.

Additional Information

SPDR S&P Biotech ETF (United States) is an exchange-traded fund (ETF), with assets under management totaling $10.39 billion.

Over the past 12 months, SPDR S&P Biotech ETF recorded a return of 64.67%, with its price trading between $95.60 and $169.55 during the same period.

The ETF is traded under the ticker XBI.